Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9H444

UPID:
CHM4B_HUMAN

ALTERNATIVE NAMES:
Chromatin-modifying protein 4b; SNF7 homolog associated with Alix 1; SNF7-2; Vacuolar protein sorting-associated protein 32-2

ALTERNATIVE UPACC:
Q9H444; E1P5N4; Q53ZD6

BACKGROUND:
The protein Charged multivesicular body protein 4b, known under various names such as SNF7-2, is a core component of the ESCRT-III complex. It is involved in critical cellular processes including MVB formation, endosomal cargo sorting, and membrane fission events. Its role is also significant in viral budding, particularly in the release of HIV-1.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in the pathogenesis of Cataract 31, multiple types, targeting CHMP4B offers a promising avenue for developing novel therapeutic interventions for this and potentially other ESCRT-III related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.